Health Tech Capitol | Exact Sciences’ Cologuard market expands by 20+ million with new American Cancer Society guidelines
16285
post-template-default,single,single-post,postid-16285,single-format-standard,tribe-no-js,tribe-bar-is-disabled,ajax_fade,page_not_loaded,,qode-child-theme-ver-1.0.0,qode-theme-ver-9.3,wpb-js-composer js-comp-ver-4.12,vc_responsive

Exact Sciences’ Cologuard market expands by 20+ million with new American Cancer Society guidelines

01 Jun Exact Sciences’ Cologuard market expands by 20+ million with new American Cancer Society guidelines

Posted at 14:34h in Uncategorized by
0 Likes

Exact Sciences Corp., the Madison-based company behind the Cologuard take-home, stool DNA-based colorectal cancer test, is planning to expand Cologuard to allow testing for those 45 and older following new guidelines from the American Cancer Society recommending colon cancer screening begin at age 45.

Cologuard currently is available to individuals age 50 and older who are at average risk for colorectal cancer, but the population of those 45 to 49 sharply expands the market for Cologuard by more than 20 million Americans.

In a news release this week, Exact Sciences said it had “affirmed its commitment to seek U.S. Food and Drug Administration approval” for making Cologuard available to those in that lowered age group.

Read more at the Milwaukee Business Journal

No Comments

Sorry, the comment form is closed at this time.